Clasado Biosciences Partners with Prokopton SAS to Expand Bimuno GOS Distribution in France

Clasado Biosciences, a developer of prebiotic ingredients and product solutions for the gut microbiome, has announced the appointment of Prokopton SAS as its strategic distribution partner in France.¹ This agreement extends the reach of Clasado’s proprietary ingredient, Bimuno galactooligosaccharide (GOS), into one of Europe's largest markets for prebiotic products. Under the terms of the partnership, Prokopton, based in Éguilles, France, will distribute the ingredient to commercial brands and manufacturers operating within the food and beverage, dietary supplement, and pet nutrition sectors.

What is the Strategic Context of the French Prebiotics Market?

The distribution agreement aligns with positive commercial projections for the French functional ingredient landscape. According to data cited by Clasado, the prebiotic market in France is projected to grow at a compound annual growth rate (CAGR) of 7.26%, reaching an estimated value of $387.91 million by the year 2032.

Data regarding consumer behavior in the region highlights a strong market receptivity toward gut health solutions. The company also highlights industry insights from FMCG Gurus indicating that French consumers frequently take a proactive, rather than reactive, approach to wellness management. Specifically, 51% of consumers in France express interest in digestive health products even when they are not experiencing active health symptoms. Furthermore, general awareness of prebiotics among the French population has reached 55%, with 42% of those aware individuals purchasing a product featuring prebiotic benefits within the preceding twelve months.

What are Executive Perspectives on the Distribution Agreement?

Representatives from both organizations emphasized that consumer trends and ingredient versatility were foundational drivers for the partnership. Annika Malmros, Director of Business Development at Clasado, noted that the collaboration reflects a corporate commitment to streamlining access to Bimuno GOS for manufacturers across the European region. “Prokopton has a well-established position across supplements, food and beverage, and pet nutrition sectors, combined with a deep understanding of the French market,” she explains. “As such, it’s exactly the right partner to support brands looking to meet growing consumer demand with a prebiotic ingredient they can stand behind.”

Yazan El Safadi, Managing Director at Prokopton, stated that French consumers actively make deliberate health choices, recognizing the foundational role that gut health plays in overall wellbeing and lifespan. “That’s exactly the kind of consumer environment where Bimuno GOS thrives: a market that’s ready for an ingredient with real science behind it, not just a trend label,” El Safadi states. “We rarely come across ingredients with such a solid scientific backing, and Bimuno GOS earns its place.”

What does the Formulation Versatility and Scientific Portfolio Look Like?

Bimuno GOS is an ingredient designed to selectively stimulate the growth of beneficial gut bacteria, particularly Bifidobacteria. This bacterial group is linked to the support of gastrointestinal, immune, and cognitive health, the company notes, also stating that Bimuno GOS stands as the most widely studied prebiotic of its specific class. Its foundational research portfolio includes more than 130 scientific publications and incorporates data from over 25 individual clinical trials.

From a manufacturing perspective, the ingredient is characterized by formulation versatility across diverse product formats. This physical adaptability allows it to be integrated into various matrices, aligning with the varied formulation requirements of manufacturers for the French marketplace.

Additionally, recent research on Bimuno GOS examined its effect on GI wellness and immune support. Earlier this year, Clasado Biosciences announced results from a randomized, placebo-controlled trial on the potential of the prebiotic to support gut health and immune function in athletic populations.² The results included the reduction of GI symptoms and of upper respiratory symptoms in the participants.

“For formulators in sports nutrition, it’s a highly compelling proposition – clinical efficacy in athlete cohorts combined with increasing awareness of gut health from performance-conscious consumers,” explained Lucien Harthoorn, R&D Director at Clasado.

This article was created with assistance from AI. The content has been reviewed and edited by Erin McEvoy, Associate Editor. For more information on the extent and nature of AI usage, please contact us.

References

1. Clasado extends the reach of Bimuno® GOS into the French market, appointing Prokopton as new distributor. Clasado Biosciences. May 27, 2026. Accessed June 3, 2026. https://clasado.com/clasado-extends-the-reach-of-bimuno-gos-into-the-french-market-appointing-prokopton-as-new-distributor/
2. McEvoy E. Clasado Biosciences Highlights Bimuno GOS Potential for Gut and Immune Support in Athletes. March 30, 2026. Accessed June 3, 2026. https://www.nutritionaloutlook.com/view/clasado-biosciences-highlights-bimuno-gos-potential-for-gut-and-immune-support-in-athletes